Because of their convenience, oral dosage forms are an emerging trend in companion animal formulations. Ectoparasiticides represent a significant proportion of the treatments administered to pets, and recently oral fo...Because of their convenience, oral dosage forms are an emerging trend in companion animal formulations. Ectoparasiticides represent a significant proportion of the treatments administered to pets, and recently oral formulations have been commercialized. They have to demonstrate high palatability to ensure that they are voluntarily accepted by the animal especially because they are repeatedly offered medications. The present study aimed to compare the dog’s preference between two commercially available oral ectoparasiticide formulations containing either afoxolaner (NexGard®, Merial) or fluralaner (Bravecto®, MSD Animal Health). In two separate experiments, 225 individual dogs (115 and 110 respectively) were offered a choice of afoxolaner or fluralaner chewable tablets. The 225 dogs were given an opportunity to smell both products, and then the products were simultaneously offered to each dog by hand for 4 consecutive days with products offered from alternate hands on each day. Individual consumption and related behaviors were recorded. The same individual offered the products to the dogs throughout each study. The total number of chewable tablets for each formulation was recorded and preference was evaluated as the consumption of a given formulation during more days. A total amount of 797 tablets were consumed by the 225 dogs during the 4 days of the studies. A total of 573 (71.9%) afoxolaner chews and 224 (28.1%) fluralaner chews were consumed voluntarily. The overall consumption ratio was 2.56 to 1 for NexGard®?to Bravecto®, with significantly (p ®?than Bravecto®?on each day. As for dogs demonstrating a preference over the entire test period;83% of the dogs tested preferred NexGard®?to Bravecto®, resulting in a preference ratio of 5 to 1 for afoxolaner formulation versus fluralaner formulation. This study demonstrated that when dogs were offered a choice between the two ectoparasiticide products, a significant preference for NexGard®?was observed.展开更多
The objective of the study was to compare the efficacy of one topical insecticide-acaricide (Frontline Tri-Act?) and of one collar (Seresto?) against fleas (Ctenocephalides felis) and ticks (Rhipicephalus sanguineus) ...The objective of the study was to compare the efficacy of one topical insecticide-acaricide (Frontline Tri-Act?) and of one collar (Seresto?) against fleas (Ctenocephalides felis) and ticks (Rhipicephalus sanguineus) on dogs exposed to bi-weekly water showering. Twenty four (24) dogs were enrolled in the study. A first set of 16 dogs were acclimatised to their cages from Day 1 to 7 and a second set of 8 dogs from Day 163 to Day 169. The 24 dogs were randomly allocated to three groups (1 to 3). Dogs assigned to Group 1 were not treated and served as negative controls. Dogs assigned to Group 2 received the Seresto? collar on Day 0 and dogs in Group 3 received Frontline Tri-Act? on Days 170 and 198. The dogs were observed hourly for four hours after treatment administration for possible adverse reactions. Dogs in Groups 1 and 2 underwent water showering on Days 14, 28, 42, 56, 70, 84, 98, 112, 126, 143 and 157. Dogs in all groups underwent water showering on Days 173, 185, 199 and 213. Dogs were infested with approximately 100 (±4) adult, unfed C. felis fleas only on Days 177, 190, 203, and 217, in alternance with infestations with 50 adult unfed R. sanguineus on Days 182, 196, 210, and 224, to assess sustained efficacy. Fleas and ticks were removed and counted on 24 and 48 hours ± 2 hours after each infestation, respectively. Frontline Tri-Act? was >99% effective against C. felis following an initial and a second monthly administration on dogs that were water showered bi-weekly. The Seresto? collar was from 68.3% to 92.9% effective against C. felis Days 178 to 218 after collar administration. Frontline Tri-Act? was effective from 87.8% to 100% against ticks whereas Seresto collar was effective from 82.2% to 94.2% from Day 184 to Day 226.展开更多
文摘Because of their convenience, oral dosage forms are an emerging trend in companion animal formulations. Ectoparasiticides represent a significant proportion of the treatments administered to pets, and recently oral formulations have been commercialized. They have to demonstrate high palatability to ensure that they are voluntarily accepted by the animal especially because they are repeatedly offered medications. The present study aimed to compare the dog’s preference between two commercially available oral ectoparasiticide formulations containing either afoxolaner (NexGard®, Merial) or fluralaner (Bravecto®, MSD Animal Health). In two separate experiments, 225 individual dogs (115 and 110 respectively) were offered a choice of afoxolaner or fluralaner chewable tablets. The 225 dogs were given an opportunity to smell both products, and then the products were simultaneously offered to each dog by hand for 4 consecutive days with products offered from alternate hands on each day. Individual consumption and related behaviors were recorded. The same individual offered the products to the dogs throughout each study. The total number of chewable tablets for each formulation was recorded and preference was evaluated as the consumption of a given formulation during more days. A total amount of 797 tablets were consumed by the 225 dogs during the 4 days of the studies. A total of 573 (71.9%) afoxolaner chews and 224 (28.1%) fluralaner chews were consumed voluntarily. The overall consumption ratio was 2.56 to 1 for NexGard®?to Bravecto®, with significantly (p ®?than Bravecto®?on each day. As for dogs demonstrating a preference over the entire test period;83% of the dogs tested preferred NexGard®?to Bravecto®, resulting in a preference ratio of 5 to 1 for afoxolaner formulation versus fluralaner formulation. This study demonstrated that when dogs were offered a choice between the two ectoparasiticide products, a significant preference for NexGard®?was observed.
文摘The objective of the study was to compare the efficacy of one topical insecticide-acaricide (Frontline Tri-Act?) and of one collar (Seresto?) against fleas (Ctenocephalides felis) and ticks (Rhipicephalus sanguineus) on dogs exposed to bi-weekly water showering. Twenty four (24) dogs were enrolled in the study. A first set of 16 dogs were acclimatised to their cages from Day 1 to 7 and a second set of 8 dogs from Day 163 to Day 169. The 24 dogs were randomly allocated to three groups (1 to 3). Dogs assigned to Group 1 were not treated and served as negative controls. Dogs assigned to Group 2 received the Seresto? collar on Day 0 and dogs in Group 3 received Frontline Tri-Act? on Days 170 and 198. The dogs were observed hourly for four hours after treatment administration for possible adverse reactions. Dogs in Groups 1 and 2 underwent water showering on Days 14, 28, 42, 56, 70, 84, 98, 112, 126, 143 and 157. Dogs in all groups underwent water showering on Days 173, 185, 199 and 213. Dogs were infested with approximately 100 (±4) adult, unfed C. felis fleas only on Days 177, 190, 203, and 217, in alternance with infestations with 50 adult unfed R. sanguineus on Days 182, 196, 210, and 224, to assess sustained efficacy. Fleas and ticks were removed and counted on 24 and 48 hours ± 2 hours after each infestation, respectively. Frontline Tri-Act? was >99% effective against C. felis following an initial and a second monthly administration on dogs that were water showered bi-weekly. The Seresto? collar was from 68.3% to 92.9% effective against C. felis Days 178 to 218 after collar administration. Frontline Tri-Act? was effective from 87.8% to 100% against ticks whereas Seresto collar was effective from 82.2% to 94.2% from Day 184 to Day 226.